AlphaCleanse: Registered 12-Week Clinical Study (ClinicalTrials.gov NCT07738744)
We put AlphaCleanse through a clinical study and registered it on ClinicalTrials.gov under the identifier NCT07738744.
No law required that. A dietary supplement can sell for a decade without anyone measuring what it does.
The design, the participant count, the dates and the full list of outcomes now sit on a public government registry we cannot revise after the fact. Open the entry, hold it against this page, and the check takes about 10 seconds.
The study ran at Citruslabs in Las Vegas, Nevada. We paid for it, under our former name Eden Boost, and the registry names us as sponsor, which is why this page does not call the study independent.
Here is the short version. Digestive symptom scores fell 38.6%, fatigue fell 24.0% and energy ratings rose 31.1%, each at p under 0.0001.
Alkaline phosphatase, measured by a Labcorp laboratory, fell 10.6%. 37 of the 40 adults finished all 12 weeks.
The same Labcorp panel carries ALT and AST, the 2 markers most people actually want to know about in a liver supplement. Those results are not published yet, and this page says exactly where they will appear.
What the study measured
In short: 6 blood markers on a Labcorp hepatic panel, plus 5 self-reported symptoms. The registry fixes that list.
The primary outcomes came off a standard hepatic function panel, drawn once at the start and once at week 12.
The secondary outcomes were self-reported. Participants scored their symptoms at baseline and again at weeks 4, 8 and 12, using the Gastrointestinal Symptom Rating Scale for digestion and the Multidimensional Fatigue Inventory for fatigue.
| Outcome | Registered as | How it was measured | When |
|---|---|---|---|
| ALT (SGPT) | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| AST (SGOT) | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| Alkaline phosphatase | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| Bilirubin | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| Albumin | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| Total protein | Primary | Blood, Labcorp hepatic function panel | Baseline and week 12 |
| Abdominal bloating | Secondary | Self-reported questionnaire | Baseline, weeks 4, 8 and 12 |
| Abdominal pain | Secondary | Self-reported questionnaire | Baseline, weeks 4, 8 and 12 |
| Fatigue | Secondary | Self-reported questionnaire | Baseline, weeks 4, 8 and 12 |
| Nausea | Secondary | Self-reported questionnaire | Baseline, weeks 4, 8 and 12 |
| Energy level | Secondary | Self-reported questionnaire | Baseline, weeks 4, 8 and 12 |
That list is the whole list, and it works as a fence in both directions: the outcomes we registered are the outcomes we owe you, and no outcome can be added later to flatter a result.
What people reported: digestion, fatigue and energy
In short: digestion fell 38.6%, fatigue 24.0%, energy rose 31.1%, each at p under 0.0001, computed on the 37 who finished.
Every change below compares week 12 with the same person's own starting point, because there was no comparison group.
A p-value under 0.05 is conventionally called statistically significant. It means the change is unlikely to be chance, and on its own it does not mean AlphaCleanse caused it.
These 3 are registered secondary outcomes, and they are what the study was built around, because the entry criteria selected people for fatigue and digestive symptoms.
The digestive score did not jump and then flatten. It fell at every check-in:
- Week 4: -26.6% against baseline.
- Week 8: -32.8%.
- Week 12: -38.6%.
That is the shape you would hope to see. It is also the shape you would see from people settling into a study and paying closer attention to how they eat, which is what the limitations section is for.
Three more questionnaire items were scored alongside the 2 totals. The registry names fatigue and energy as outcomes but does not name these separately, so read them as supporting detail rather than registered results:
- Feeling run-down or sick: -36.8%.
- Disrupted or difficult sleep: -30.5%.
- Daytime tiredness or sleepiness: -27.9%.
The registry lists bloating, abdominal pain, fatigue, nausea and energy as 5 separate secondary outcomes. Fatigue and energy are in the table above.
Bloating, abdominal pain and nausea have not been published as individual items. They sit inside the GSRS total, and they are on the list of results we owe you.
The one blood result published so far: alkaline phosphatase
In short: alkaline phosphatase fell from 86.6 to 77.4 IU/L, down 10.6%, at p=0.0145. It is the only blood result published.
Alkaline phosphatase is an enzyme made by the liver and the bile ducts, and it is 1 of the 6 registered primary outcomes.
That figure came off a Labcorp panel rather than a questionnaire, which makes it the part of this study least exposed to what anybody hoped would happen.
It is also the only blood marker that moved significantly, and the only 1 of the 6 we have published. The next section says where the other 5 stand.
What was measured but is not yet published
In short: ALT, AST, bilirubin, albumin and total protein were drawn at both visits. The values are not published, and we will post them.
Alkaline phosphatase is the only blood result we have published. The other 5 primary outcomes were measured on the same panel, from the same 2 blood draws, in the same 37 people.
Here is where they stand:
- Measured. ALT, AST, bilirubin, albumin and total protein all came off the Labcorp hepatic function panel at baseline and at week 12.
- Not published. No baseline mean, week-12 mean, percentage change or p-value for any of the 5 appears anywhere, including on this page. We will not print an estimate in the meantime.
- Not on the registry either. The ClinicalTrials.gov entry describes the study and does not carry results. Anyone can verify that in the results section of NCT07738744.
- Going up. We will post them to the registry, whichever way they moved, and add them to this page on the same day. We have not committed to a date and will not invent one here.
The adverse events recorded during the study, and the reasons the 3 participants did not finish, are in the same position: recorded, not yet published, and part of what gets posted.
If you are reading this page to decide whether ALT and AST improved, the honest answer is that we measured it, the trial was not built around that question, and the numbers are not ours to show you until they are published in full.
Nobody in this study was enrolled for a liver-test result
In short: the registry sets no liver-test entry criterion. Nobody joined with enzymes to bring down, which is how to read the pending results.
The live question in this category is not whether a liver supplement helps. It is whether it hurts.
Herbal products land in the NIH's LiverTox database every year, and for most supplements on the shelf nobody has put that question to a laboratory at all, because nothing in US supplement law requires it.
We put it to a laboratory. 40 adults took AlphaCleanse every day for 12 weeks, with a Labcorp hepatic function panel drawn at baseline and again at week 12.
What that panel showed for ALT and AST is not published, so we do not characterise it here in either direction. It goes to NCT07738744, and onto this page, when it is.
There is a second thing worth knowing before those numbers land, and this one is on the registry today. Look at who was recruited. The entry criteria are:
- Male or female, aged 40 to 65.
- Struggling with low energy and fatigue over the previous 4 weeks.
- At least 2 of: abdominal bloating, abdominal discomfort, constipation, diarrhea, or general digestive discomfort.
- Willing to hold diet, sleep and exercise steady for the 12 weeks.
There is no liver-test entry criterion anywhere in that list. Nobody was enrolled for a raised ALT, and nobody was turned away for a normal one. Read the eligibility section of NCT07738744 and you can confirm that in under a minute.
A cohort assembled that way is not a cohort with elevated enzymes waiting to come down. An enzyme already sitting inside the normal range has nowhere to fall.
So when the ALT and AST results are published, that is the frame to read them in. This study was never built to ask whether a raised liver enzyme comes down, and judging it on that question will mislead you whichever way the numbers went.
If you are weighing AlphaCleanse against another liver supplement, here is the comparison worth making. Search ClinicalTrials.gov for the other product by name and read what the registry returns.
What participants said at week 12
In short: 28 of 37 finishers reported less bloating. All of this is self-report at the end of the study, not measurement.
At week 12 the participants rated their own experience against a set of statements. The figures show how many agreed or strongly agreed, out of the 37 who completed.
These were not registered outcomes. They print here under their own heading so nobody has to work out which figures were registered and which were not.
Read the bottom of that table as carefully as the top. On the statement about energy, 19 of 37 agreed, which means 18 did not.
Everything in this section is self-reported and none of it is a blood test. The blood tests are in the 2 sections above.
Who took part, and who was excluded
In short: 40 US adults aged 40 to 65 with fatigue plus at least 2 digestive symptoms. 37 finished all 12 weeks.
Participants were men and women aged 40 to 65 living in the United States, reporting low energy or fatigue over the previous 4 weeks plus at least 2 digestive symptoms.
The study excluded:
- Anyone pregnant, breastfeeding or trying to conceive.
- Anyone on warfarin or antiplatelet therapy such as clopidogrel or aspirin.
- Anyone with a history of kidney stones, or with uncontrolled diabetes, high blood pressure or thyroid conditions.
- Anyone with a severe digestive disorder, including IBS, IBD, Crohn's, ulcerative colitis, ulcers, reflux or previous digestive surgery.
- Smokers, and anyone allergic to an ingredient.
Those exclusions are ordinary caution in a first study of a botanical product, and they are why our FAQ tells the same groups to ask a doctor first.
They are not evidence that the product harms those groups. Nobody in them was studied, which is a different statement and a weaker one.
40 people enrolled and 37 completed the 12 weeks, a completion rate of 92.5%.
Limitations, in plain words
In short: single arm, no placebo, 40 people, open label, registered after completion, sponsor funded, results not yet posted.
These are the reasons to hold every number above loosely. They are on this page because a result you cannot interrogate is not worth much, and because the registry makes most of them checkable anyway.
Single arm, no placebo. Everyone took AlphaCleanse. Bloating and fatigue ease on their own in plenty of people over 12 weeks, and being in a study changes how people eat and sleep.
Some share of the improvement would have shown up with a sugar pill, and this design cannot say how much.
Open label. Participants and staff knew what was being taken, and self-reported scores move with expectation. That is why the blood result, measured by a laboratory with no stake in the answer, carries more weight than the questionnaires.
40 people. Small enough that a few strong responders can move an average, and far too small to detect uncommon side effects.
Registered after completion. The registration was filed on 28 July 2026 and the study had finished on 15 January 2026.
You can still check that the outcomes we report are the ones the study set out to measure. This is not the pre-registration a large drug trial carries, where the plan goes public before the first participant enrols.
Sponsor funded. We paid for it. Citruslabs ran it at their site and did the analysis, and a study paid for by the company selling the product deserves the caution you would apply to any industry-funded research.
Results not yet on the registry. The ClinicalTrials.gov entry describes the study and carries no results, and 5 of the 6 primary outcomes are unpublished.
Every one of those 6 is checkable against the registry entry, which is the reason they are printed here instead of left for somebody else to find.
What this study does and does not tell you
In short: it describes what happened to 37 adults over 12 weeks. It does not establish that AlphaCleanse caused it.
It does not tell you that AlphaCleanse caused those changes, because there was no control group.
It does not tell you what happens in people with raised ALT or AST, who were not recruited. It says nothing about use beyond 12 weeks, about people under 40 or over 65, or about any of the excluded groups.
And until the remaining 5 blood markers are published, it does not tell you the size or direction of the change in bilirubin, albumin or total protein.
What it does tell you is what happened to 40 adults with fatigue and digestive symptoms who took AlphaCleanse daily for 12 weeks:
- Digestive symptom and fatigue scores fell, and self-rated energy rose, each at p under 0.0001.
- Alkaline phosphatase fell from an average of 86.6 to 77.4 IU/L, p=0.0145.
- A Labcorp hepatic panel was drawn at baseline and week 12; 5 of its 6 markers, ALT and AST among them, are not yet published.
- 37 of the 40 stayed to the end.
All of it either measured at a laboratory or scored on questionnaires, with 5 of the 6 registered blood outcomes still to be published.
How to check this page
In short: open the registry entry and read it against what you have just read here.
Open https://clinicaltrials.gov/study/NCT07738744. The 6 blood markers and the 5 symptom outcomes listed there are what the study measured, so that list doubles as the list of results we owe you, including the 5 still pending above.
We publish them whichever way they moved, and the registry is the record that holds us to it.
Then read the reviews, worst ratings first, and read the FAQ, which covers who should not take AlphaCleanse and which prescriptions to raise with a pharmacist before starting.
If you decide to try it after all that, 60 days is long enough to run the bottle and decide for yourself. 60-day money-back guarantee, counted from delivery, no questions asked and no restocking fee; we may ask you to send any unused bottles back.
AlphaCleanse: https://liverated.co/pages/alphacleanse
Last reviewed 17 September 2026 by Wilson Lau, co-founder, Liverated. Registry entry last checked 9 September 2026; published figures re-read against the live page on 17 September 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.